Tumor progression: The effects of thrombospondin-1 and -2

International Journal of Biochemistry and Cell Biology

Volumn 36, Issue 6, 2004, Pages 1038-1045

  Lawler, Jack ^a   Detmar, Michael ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Angiogenesis; Cancer; Thrombospondin; Tumor

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; ENDOSTATIN; MATRIX METALLOPROTEINASE; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; SYNTHETIC PEPTIDE; THROMBOSPONDIN 1; THROMBOSPONDIN 2; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; CANCER; CANCER CHEMOTHERAPY; CELL MIGRATION; CLINICAL TRIAL; DOWN REGULATION; ENDOTHELIUM CELL; ENZYME ACTIVATION; GENE ACTIVATION; GENE THERAPY; HUMAN; LOW DRUG DOSE; NONHUMAN; ONCOGENE; PATHOGENESIS; PHENOTYPE; REVIEW; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

EID: 4444353257     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2004.01.008     Document Type: Short Survey

References (42)

1. Abraham D., Abri S., Hofmann M., Holtl W., Aharinejad S. Low dose carboplatin combined with angiostatic agents prevents metastasis in human testicular germ cell tumor xenografts. Journal of Urology. 170:2003;1388-1393.
2. Armstrong L.C., Bornstein P. Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biology. 22:2003;63-71.
3. Bein K., Simons M. Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity. Journal of Biological Chemistry. 275:2000;32167-32173.
4. Bocci, G., Francia, Man, S., Lawler, J., & Kerbel, R. S. (2003). Thrombospondin-1 a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proceedings of the National Academy of Science of the United States of America, 100, 12917-12922.
5. Browder T., Butterfield C.E., Kraling B.M., Shi B., Marshall B., O'Reilly M.S.et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Research. 60:2000;1878-1886.
6. Cline E.I., Bicciato S., DiBello C., Lingen M.W. Prediction of in vivo synergistic activity of antiangiogenic compounds by gene expression profiling. Cancer Research. 62:2002;7143-7148.
7. Dawson D.W., Volpert O.V., Pearce S.F.A., Schneider A.J., Silverstein R.L., Henkin J.et al. Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. Molecular Pharmacology. 55:1999;332-338.
8. de Fraipont F., Nicholson A.C., Feige J.J., Van Meir E.G. Thrombospondins and tumor angiogenesis. Trends in Molecular Medicine. 7:2001;401-407.
9. De Vos, F. Hoekstra, R., Gietema, J., Eskens, F., van der Gaast, A., Carr, R. et al. (2002). A phase I dose escalating study of the angiogenesis inhibitor thrombospondin-mimetic (ABT-510) in patients with advanced cancer. In Proceedings of the American Journal of Society and Clinical Oncology (Abstract no. 324).
10. Dejong V., Degeorges A., Filleur S., Ait-Si-Ali S., Mettouchi A., Bornstein P.et al. The Wilms' tumor gene product represses the transcription of thrombospondin 1 in response to overexpression of c-Jun. Oncogene. 18:1999;3143-3151.
11. Detmar M. The role of VEGF and thrombospondins in skin angiogenesis. Journal of Dermatological Science. 24(Suppl. 1):2000;S78-S84.
12. Filleur S., Volpert O.V., Degeorges A., Voland C., Reiher F., Clezardin P.et al. In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects. Genes Development. 15:2001;1373-1382.
13. Filleur S., Courtin A., Ait-Si-Ali S., Guglielmi J., Merle C., Harel-Bellan A.et al. SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Research. 63:2003;3919-3922.
14. Gordon M., Mendelson D., Guirguis M., Knight R., Humerickhouse R., Stopeck A.et al. ABT-510 an anti-angiogenic, thrombospondin-1 (TSP-1) mimetic peptide, exhibits favorable safety profile and early signals of activity in a randomized phase IB trial. Proceedings of the American Society for Clinical Oncology. 22:2003;195. [Abstract no. 780].
15. Guo N.-H., Drutzch H.C., Inman J.K., Roberts D.D. Thrombospondin 1 and type 1 repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Research. 57:1997;1735-1742.
16. Min/+ mouse model. Carcinogenesis. 24:2003;199-207.
17. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70.
18. Hawighorst T., Velasco P., Streit M., Hong Y.K., Kyriakides T.R., Brown L.F.et al. Thrombospondin-2 plays a protective role in multistep carcinogenesis: A novel host anti-tumor defense mechanism. EMBO Journal. 20:2001;2631-2640.
19. Hawighorst T., Oura H., Streit M., Janes L., Nguyen L., Brown L.F.et al. Thrombospondin-1 selectively inhibits early-stage epithelial carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice. Oncogene. 21:2002;7945-7956.
20. Iruela-Arispe M.L., Lombardo M., Krutzsch H.C., Lawler J., Roberts D.D. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation. 100:1999;1423-1431.
21. Janz A., Sevignani C., Kenyon K., Ngo C.V., Thomas-Tikhonenko A. Activation of the myc oncoprotein leads to increased turnover of thrombospondin-1 mRNA. Nucleic Acids Research. 28:2000;2268-2275.
22. Jimenez B., Volpert O.V., Crawford S.E., Febbraio M., Silverstein R.L., Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nature of Medicine. 6:2000;41-48.
23. Lawler J., Miao W.M., Duquette M., Bouck N., Bronson R.T., Hynes R.O. Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice. American Journal of Pathology. 159:2001;1949-1956.
24. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. Journal of Cellular and Molecular Medicine. 6:2002;1-12.
25. Lyden D., Hattori K., Dias S., Costa C., Blaikie P., Butros L.et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nature Medicine. 7:2001;1194-1201.
26. Miao W., Seng W.L., Duquette M., Lawler P., Laus C., Lawler J. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-b-dependent and -independent mechanisms. Cancer Research. 61:2001;7830-7839.
27. Noh Y.-H., Matsuda K., Hong Y.-K., Kunstfeld R., Riccardi L., Koch M.et al. An N-terminal 80 kDa recombinant fragment of human thrombospondin-2 inhibits vascular endothelial growth factor induced endothelial cell migration in vitro and tumor growth and angiogenesis in vivo. The Journal of Investigative Dermatology. 121:2003;1536-1543.
28. Reiher F.K., Volpert O.V., Jimenez B., Crawford S.E., Dinney C.P., Henkin J.et al. Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. International Journal of Cancer. 98:2002;682-689.
29. Rodriguez-Manzaneque J.C., Lane T.F., Ortega M.A., Hynes R.O., Lawler J., Iruela-Arispe M.L. Thrombospondin-1 supresses tumor growth by a novel mechanism that includes blockade of matrix matalloproteinase-9 activation. Proceedings of the National Academy of Science of the United States of America. 98:2001;12485-12490.
30. Rofstad E.K., Henriksen K., Galappathi K., Mathiesen B. Antiangiogenic treatment with thrombospondin-1 enhances primary tumor radiation response and prevents growth of dormant pulmonary micrometastases after curative radiation therapy in human melanoma xenografts. Cancer Research. 63:2003;4055-4061.
31. Sargiannidou I., Zhou J., Tuszynski G.P. The role of thrombospondin-1 in tumor progression. Experimental Biology and Medicine. 226:2001;726-733.
32. Schwarte-Waldhoff I., Volpert O.V., Bouck N.P., Sipos B., Hahn S.A., Klein-Scory S.et al. Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proceedings of the National Academy of Science of the United States of America. 97:2000;9624-9629.
33. Streit M., Stephen A.E., Hawighorst T., Matsuda K., Lange-Asschenfeldt B., Brown L.F.et al. Systemic inhibition of tumor growth and angiogenesis by thrombospondin-2 using cell-based antiangiogenic gene therapy. Cancer Research. 62:2002;2004-2012.
34. Su J.D., Mayo L.D., Donner D.B., Durden D.L. PTEN and phosphatidylinositol 3′-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: Evidence for an effect on the tumor and endothelial compartment. Cancer Research. 63:2003;3585-3592.
35. Tan K., Duquette M., Liu J.H., Dong Y., Zhang R., Joachimiak A.et al. Crystal structure of the TSP-1 type 1 repeats: A novel layered fold and its biological implication. Journal of Cell Biology. 159:2002;373-382.
36. Tolsma S.S., Volpert O.V., Good D.J., Frazier W.A., Polverini P.J., Bouck N. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. Journal of Cell Biology. 122:1993;497-511.
37. Volpert O.V., Pili R., Sikder H.A., Nelius T., Zaichuk T., Morris C.et al. Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1a. Cancer Cell. 2:2002;473-483.
38. Watnick R.S., Cheng Y.N., Rangarajan A., Ince T.A., Weinberg R.A. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell. 3:2003;219-231.
39. Wen S., Stolarov J., Myers M.P., Su J.D., Wigler M.H., Tonks N.K.et al. PTEN controls tumor-induced angiogenesis. Proceedings of the National Academy of Science of the United States of America. 98:2001;4622-4627.
40. Yang Q.W., Liu S., Tian Y., Salwen H.R., Chlenski A., Weinstein J.et al. Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma. Cancer Research. 63:2003;6299-6310.
41. Yoo G.H., Piechocki M.P., Ensley J.F., Nguyen T., Oliver J., Meng H.et al. Docetaxel induced gene expression patterns in head and neck squamous cell carcinoma using cDNA microarray and PowerBlot. Clinical Cancer Research. 8:2002;3910-3921.
42. Zhang Y.-W., Su Y., Volpert O.V., Vande Woude G.F. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proceedings of the National Academy of Science of the United States of America. 100:2003;12718-12723.